Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsOrphan-drug designation does not approve a medicine or automatically give it seven years of exclusivity. The conflict arises after approval: FDA generally ties orphan-drug exclusivity to the approved use, while the Eleventh Circuit held in 2021 that the statutory protection can cover the entire rare disease for which the drug was designated. That ruling applies within the Eleventh Circuit; the available later-dated overview of the dispute, from the Congressional Research Service on March 5, 2024, says FDA continued to follow its own interpretation.
What orphan-drug designation means—and what it does not
The Orphan Drug Act provides a route for developing drugs and biological products for rare diseases or conditions. The statutory criteria include diseases affecting fewer than 200,000 people in the United States, or diseases affecting more people when development costs are not reasonably expected to be recovered from U.S. sales. FDA explains the designation process on its orphan-product designation page.
Designation and permission to market are separate steps. FDA states that “Orphan drug designation is a separate process from seeking approval or licensing.” A sponsor may seek designation while developing a product, but designation alone does not establish that the product is safe and effective for a particular use, authorize its sale, or start the statutory exclusivity period.
Designation can make a sponsor eligible for incentives such as potential tax credits for qualified clinical trials and exemption from certain user fees. Those incentives are not marketing approval, and eligibility for them is not a guarantee that FDA will approve the drug.
#1 Best Overall
When the seven-year exclusivity period starts
The statute provides seven years of orphan-drug exclusivity after a qualifying drug is approved or licensed for its designated rare disease or condition. It does not grant seven years merely because FDA has designated a product. The statutory excerpts published by FDA set out the period and its exceptions.
During the applicable period, the statute generally bars FDA from approving another application for the same drug for the same rare disease or condition. The bar has exceptions: the original holder may consent, or FDA may find that the holder cannot assure sufficient quantities of the drug to meet the needs of patients with the disease or condition.
Rank #2
- Lawyer gifts for women Gifts Bookmark for Women Men: The best gifts for lawyers—who are perpetually busy—are those that inspire them after a demanding day at work. Lawyer gifts for women, law school gifts, cool gifts for attorneys, stocking stuffers for lawyers, your book-loving friends or family can keep them in a favorite book to quickly find beloved pages
- Law School Graduation Gifts Bookmark for Him Her: Law graduation gifts for law students, future lawyers;back to school supplies, encouragement lawyer gift for Christmas, Valentine's Day, Fathers Day, Mothers Day, birthday, white elephant, employee appreciation day to an important law practitioner in your life, a newly qualified lawyer, or someone who works with law
- Attorney Gifts for Men Women: Inspirational gifts for lawyer, judge, attorney, law and judge students, scales of justice gifts, criminal justice graduation, lawyer attorney gift, lawyer coworker gifts. Lawyer gifts for daughter, son, sister, brother, best friends, book nerds, book worm, book lover, book enthusiasts, and all the readers, the lawyer bookmark is intended to evoke the fun memories of reading
- Quality and Service: Made of stainless steel, suitable thickness, not easy to bend deformation, hypoallergenic, does not rust, tarnish. Lawyer bookmark is a must-have for book lover Bookmark dimension: 5.11*1.02 inch
- This personalizes the bookmark and adds a touch of color. Find funny in the lawyer progress. If anything goes wrong with your order, please let us know
The difficult question is how broadly to define the protected use when the designated disease is broad but the approved label covers only a particular subgroup, mutation, or other narrower indication.
Why FDA’s interpretation and the Catalyst ruling conflict
FDA’s regulations and longstanding approach generally connect exclusivity to the approved use or indication. Under that interpretation, a different use of the same drug for the same disease may still be eligible for approval if it is not the protected approved use. The Congressional Research Service (CRS) describes this approach and the statutory dispute in its March 5, 2024 overview.
Free tools Windows power users keep installed
One-click scans. No signup required.
In Catalyst Pharmaceuticals, Inc. v. Becerra, decided September 30, 2021, the Eleventh Circuit read the statute more broadly. It held that exclusivity attaches to the entire disease or condition for which the drug received orphan designation, even if the initial approval covers only a narrower patient population. FDA summarizes the disagreement in its overview of the Catalyst decision.
| Approach | How it treats a narrower approved indication | Geographic or source qualification |
|---|---|---|
| FDA’s general interpretation | Exclusivity protects the same approved use or indication. A different use for the same disease may remain eligible for a separate approval pathway. | FDA’s stated agency interpretation; CRS reported in its March 5, 2024 account that FDA continued to use this interpretation despite the court’s disagreement. |
| Eleventh Circuit’s Catalyst interpretation | Exclusivity covers the designated disease or condition, even when the initial approved label covers a narrower population or use. | Holding of the Eleventh Circuit in the 2021 Catalyst case; it should not be treated as an automatic nationwide rule. |
FDA illustrates the practical difference with cystic fibrosis. If a drug is designated for cystic fibrosis but first approved for adults with a particular mutation, FDA’s indication-specific approach could permit consideration of the same drug for another cystic-fibrosis population. Under the Eleventh Circuit’s disease-wide reading, that approval could be blocked during the exclusivity period because the drug was designated for the broader disease.
What the dispute means when a drug has multiple uses
A designation, an approved label, and a later proposed use answer different questions. Designation identifies the rare disease or condition tied to the orphan program. The label states the specific use FDA has approved. Exclusivity is a statutory restriction on certain later approvals; its reach is the point contested in Catalyst. A drug’s approval for one patient group therefore does not, by itself, resolve whether another group may receive an approval for the same drug.
For a particular product, the relevant facts include:
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minute- The disease or condition named in the orphan designation.
- The precise approved indication and patient population in the label.
- Whether the later application concerns the same drug, rather than a different drug or active moiety.
- Where the application is being considered and what precedent governs there.
- When qualifying approval occurred and how much of any recognized exclusivity period remains.
- Whether the holder consents or FDA finds that sufficient supply cannot be assured.
- Whether separate patents or other regulatory exclusivities affect the product or proposed use.
The answer can depend on the interaction of these facts; the general rule does not determine the status of any particular drug. No specific medicine’s current designation or exclusivity status is assessed here.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How clinical superiority fits in
FDA guidance addresses a related situation: a sponsor seeking orphan designation for the same drug for the same rare disease as an already-approved drug may need a plausible hypothesis of clinical superiority. FDA identifies greater effectiveness, greater safety for a substantial portion of the target population, and—in unusual cases—a major contribution to patient care as possible bases. Potential contributions to patient care can include treatment location or duration, comfort, treatment burden, ease of administration, dosing interval, or potential self-administration; FDA says cost is not considered for this determination. These are FDA’s designation and exclusivity considerations, not a promise of approval. See the agency’s orphan-designation FAQ.
Orphan exclusivity is not patent protection
Orphan-drug exclusivity and patents are different protections. FDA describes patents as property rights granted by the U.S. Patent and Trademark Office; they may cover different aspects of a product from those covered by regulatory exclusivity. The protections can overlap or run on different schedules, and neither necessarily substitutes for the other. FDA explains the distinction in its patents and exclusivity FAQ.
What is established about the law’s current reach
The Eleventh Circuit issued its Catalyst decision on September 30, 2021. CRS’s overview dated March 5, 2024 reports that FDA continued to apply its indication-specific interpretation notwithstanding that decision. Those sources establish a conflict between the court’s reading and FDA’s general approach, but they do not establish whether later legislation or court decisions changed the landscape after their dates. The Eleventh Circuit ruling should therefore be described as controlling within its jurisdiction, not presumed to settle the issue nationally.
Recommended Free Tools
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
